Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.75 |
| ▸ | EGFR | P00533 | 6/20 | 0.49 |
| ▸ | PRKDC | P78527 | 4/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14329106 | 0.86 | LRRK2 (0.79) | LRRK2EGFRPRKDCRAF1MAP2K1 | |
| SCHEMBL14330950 | 0.86 | LRRK2 (1.00) | LRRK2EGFRPRKDCRAF1MAP2K1 | |
| SCHEMBL28690628 | 0.83 | LRRK2 (0.51) | LRRK2EGFRPRKDCERBB2AR | |
| SCHEMBL30851514 | 0.83 | LRRK2 (0.51) | LRRK2EGFRPRKDCERBB2AR | |
| SCHEMBL28690630 | 0.83 | LRRK2 (0.51) | LRRK2EGFRPRKDCERBB2AR | |
| SCHEMBL4569244 | 0.82 | LRRK2 (0.49) | LRRK2 | |
| SCHEMBL4572179 | 0.81 | LRRK2 (0.75) | LRRK2EGFRPRKDCRAF1MAP2K1 | |
| SCHEMBL12156904 | 0.79 | LRRK2 (0.72) | LRRK2EGFRPRKDCRAF1MAP2K1 | |
| SCHEMBL22749310 | 0.79 | LRRK2 (0.46) | LRRK2EGFRPRKDC | |
| SCHEMBL22749313 | 0.79 | LRRK2 (0.46) | LRRK2EGFRPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388183-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9315505-B2 | Heterocyclic compounds and uses thereof | INTELLIKINE LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8901133-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140296207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | LRRK2 549/4885EGFR 1194/4885PRKDC 62/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | LRRK2 549/4885EGFR 1194/4885PRKDC 62/4885 |
| US-20140296207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, AKT3, PIK3CD | LRRK2 876/4885EGFR 2450/4885PRKDC 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.